Determining "clinical significance" for Lyrica in Fibro: VAS goes from 6 to 5.6 after 14 weeks

Why is Lyrica considered "clinically significant" in pain control for Fibro when the studies they are quoting show a difference of VAS from 6 to 5.6 after 14 weeks? Seems odd that a 4% benefit in score allows at 700/month prescription with many side effects is somehow clinically acceptable? How does that work?
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Source Type: forums